ORIGINAL ARTICLE R. F. VAN VOLLENHOVEN, 1 D. FELSON, 2 V. STRAND, 3 M. E. WEINBLATT, 4 K. LUIJTENS, 5 AND E. C. KEYSTONE 6 INTRODUCTION
|
|
- Barbara Gibbs
- 5 years ago
- Views:
Transcription
1 Arthritis Care & Research Vol. 63, No. 1, January 2011, pp DOI /acr , American College of Rheumatology ORIGINAL ARTICLE American College of Rheumatology Hybrid Analysis of Certolizumab Pegol Plus Methotrexate in Patients With Active Rheumatoid Arthritis: Data From a 52-Week Phase III Trial R. F. VAN VOLLENHOVEN, 1 D. FELSON, 2 V. STRAND, 3 M. E. WEINBLATT, 4 K. LUIJTENS, 5 AND E. C. KEYSTONE 6 Objective. The American College of Rheumatology (ACR) hybrid (a modified mean percent response to treatment) was officially recommended by the ACR as a revision to 20%, 50%, and 70% response criteria (ACR20/50/70) scores, but has not been tested in clinical trials. We performed a post hoc analysis of a phase III study of certolizumab pegol (Rheumatoid Arthritis Prevention of Structural Damage 1 [RAPID 1]) using the ACR hybrid. Methods. Patients with active rheumatoid arthritis were randomized to certolizumab pegol (200 or 400 every other week) plus methotrexate or placebo plus methotrexate. ACR s were compared with ACR20/50/70 outcomes. Results. Differences between active treatment and placebo were significant throughout the study using the ACR20 and ACR hybrid outcomes. In the certolizumab pegol 200 group, the median ACR at week 52 (last observation carried forward) was A total of 258 (65.8%) of 392 and 172 (43.9%) of 392 patients had ACR20 and ACR50 responses, respectively. An additional 55 patients (14.0%) and 59 patients (15.1%) had mean improvements in ACR core measures of >20% and >50%, respectively, and therefore had positive ACR s, despite lacking ACR20 and ACR50 responses, respectively. In the placebo group, median ACR s were <10 at most time points; unlike other measures, the ACR hybrid measure indicated worsening scores for many patients. Conclusion. ACR hybrid analysis had greater sensitivity than traditional ACR20/50/70 criteria, demonstrating improvements in ACR20 nonresponders treated with certolizumab pegol. Negligible benefit was observed with placebo using ACR hybrid analysis. INTRODUCTION American College of Rheumatology (ACR) 20%, 50%, and 70% response criteria (ACR20/50/70), as well as the European League Against Rheumatism (EULAR) criteria and Disease Activity Score 28-joint count (DAS28), have standardized the evaluation and reporting of response in clinical trials of rheumatoid arthritis (RA) (1,2). However, these measures have limitations. The DAS28 does not give an indication of the proportion of patients who improve - ClinicalTrials.gov identifier: NCT Supported by UCB, which sponsored the clinical trial from which these analyses were performed. Dr. Felson s work was supported by the NIH (grant AR47785) and by the American College of Rheumatology (ACR) for development of the ACR hybrid. Dr. Keystone s work was supported by Abbott Laboratories, Aen, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Centocor, Inc., F. Hoffman- LaRoche, Inc., Novartis Pharmaceuticals Schering-Plough Corporation, UCB, and Wyeth Pharmaceuticals. with treatment, whereas the ACR20/50/70 and EULAR criteria are dichotomous (i.e., yes/no) and trichotomous measures of individual response, respectively, that may not be as sensitive to change as continuous measures of improvement (3). Therefore, the ACR was recently proposed and approved by the ACR as a revision to ACR20/50/70 scores (3). The ACR is designed to combine ACR20/50/70 scores with the mean percent change from baseline in all 7 ACR core set components, allowing for detection of smaller differences between active treatments while preserving ACR20/50/70 1 R. F. van Vollenhoven, MD, PhD: Karolinska Institute, Stockholm, Sweden; 2 D. Felson, MD: Boston University, Boston, Massachusetts; 3 V. Strand, MD: Stanford University, Palo Alto, California; 4 M. E. Weinblatt, MD: Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts; 5 K. Luijtens, PhD: UCB, Brussels, Belgium; 6 E. C. Keystone, MD: University of Toronto, Toronto, Ontario, Canada. 128
2 Assessing Effective Treatment for RA With ACR Hybrid Analysis 129 Table 1. ACR s (3)* ACR status <20 >20, <50 >50, <70 >70 Not ACR20 Mean % ACR20 but not ACR50 20 Mean % ACR50 but not ACR Mean % ACR70 n/a Mean % * To obtain the American College of Rheumatology (ACR) hybrid response score, take the ACR 20% response criteria (ACR20), ACR50, or ACR70 status of the patient (left column) and the mean percentage improvement in the core set measures; the ACR is then taken at the point of intersection in the table, e.g., the ACR for an ACR20 nonresponder is calculated from the mean percent change. If that mean is lower than 20%, the actual mean percent change is reported, but if that mean exceeds 20%, the highest score that patient can achieve is 19.99% ( banded to 20% ). n/a not applicable. responses as benchmarks to facilitate standardized reporting (4). The ACR therefore provides valuable information not only about whether one treatment is more efficacious than another, but also about how much each treatment group improves on average. The objective of the present post hoc analysis was to evaluate the use of the ACR hybrid measure relative to other measures of response, including ACR20/50/70 response rates and changes in the DAS28, in assessing the benefit of the PEGylated anti tumor necrosis factor agent, certolizumab pegol, when dosed at 200 or 400 every 2 weeks with methotrexate (MTX) in patients with active RA in the Rheumatoid Arthritis Prevention of Structural Damage 1 (RAPID 1) trial. Dr. van Vollenhoven has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from UCB Pharma. Dr. Strand has received consultant fees (less than $10,000 each) from Abbott Immunology, Alder, Allergan, Almirall, Aen Corporation, AstraZeneca, Biogen Idec, CBio, Can-Fite, Centocor, Chelsea, Crescendo, Cypress Biosciences, Inc., Euro-Diagnostica, Fibrogen, Forest Laboratories, Genentech, GlaxoSmithKline, Human Genome Sciences, Idera, Incyte, Jazz Pharmaceuticals, Lexicon Genetics, Lilly, Logical Therapeutics, Lux Biosciences, MedImmune, Merck Sorono, Novartis, Novo Nordisk, Nuon, Ono Pharmaceuticals, Pfizer, Rigel, Roche, Sanofi- Aventis, Savient, Schering-Plough, SKK, UCB, and XDx, and serves on the advisory boards for Abbott, Aen, Biogen Idec, BMS, Can-Fite, Centocor, Chelsea, Crescendo, Cypress, Euro-Diagnostica, Fibrogen, Forest, Genentech, GSK, HGS, Idera, Incyte, Jazz, Lilly, NicOx, Novartis, Novo Nordisk, Pfizer, Rigel, Roche, Savient, Schering-Plough, and UCB. Dr. Weinblatt has received consultant fees (less than $10,000) from UCB. Dr. Keystone has received consultant fees and/or honoraria (less than $10,000 each) and/or has served on the advisory boards for Abbott Laboratories, Aen, Inc., Bristol-Myers Squibb, Centocor, Inc., F. Hoffman-LaRoche, Inc., Genentech, Inc., Schering-Plough Corporation, UCB, and Wyeth Pharmaceuticals. Address correspondence to R. F. van Vollenhoven, MD, PhD, Karolinska Institute, Stockholm, Sweden. Ronald.van.Vollenhoven@ki.se. Submitted for publication April 3, 2009; accepted in revised form August 10, PATIENTS AND METHODS Patients. The design of the RAPID 1 trial has been published in detail previously (5). Briefly, patients with adultonset RA, defined by the ACR 1987 criteria (6 8), were randomized to 1 of 2 regimens of subcutaneous certolizumab pegol (400 at weeks 0, 2, and 4 followed by 200 or 400 ) plus MTX, or placebo plus MTX, every other week for 52 weeks. Patients who failed to achieve an ACR20 response at both weeks 12 and 14 were to be withdrawn from the study at week 16 and given the option to enter an open-label extension study of certolizumab pegol 400 every other week. Efficacy end points included ACR20/50/70 response rates and change from baseline in the DAS28 (erythrocyte sedimentation rate) (5). Calculation of ACR s. The ACR hybrid score was determined by calculating the mean percent change from baseline across the 7 ACR core set measures for each patient (limiting the maximum improvement or worsening of each core set item to 100%) and determining whether the patient achieved ACR20, ACR50, or ACR70 responses (3) (Table 1). If the mean percent change from baseline exceeded 20% in a patient who did not reach an ACR20 response, the change was set at an ACR hybrid score of 19.99; however, if the mean was lower than 20% and the patient fulfilled the ACR20 criteria, an ACR hybrid score of was given. Likewise, if the mean percent change from baseline exceeded 50% (or 70%) in a patient who did not reach an ACR50 (or ACR70) response, the change was set at an ACR of (or 69.99), and if the mean was lower than 50% (or 70%) and the patient fulfilled the ACR50 (or ACR70) criteria, ACR hybrid scores of (or 70.00) were assigned. Statistical analyses. Efficacy analyses were conducted on the intent-to-treat (ITT) population, which included all randomized patients. The comparison of ACR20/50/70 scores for each active treatment group versus placebo was tested using a logistic regression analysis, with region and treatment as factors. In the overall ITT analysis, if a patient withdrew or used rescue medication, ACR20/50/70 scores were imputed as no response. The comparison of ACR
3 130 van Vollenhoven et al s for each active treatment group versus placebo was tested using analysis of covariance (ANCOVA) on the ranks, with region and treatment as factors. If a patient withdrew or used rescue medication, ACR hybrid scores were carried forward from that point onward. As a consequence, in the detailed analysis of ACR hybrid scores, ACR20/50/70 responses were also assessed using last observation carried forward analysis. Change from baseline in the DAS28 was compared between each active treatment group and placebo using ANCOVA, with region and treatment as factors and baseline as covariate. RESULTS Patient characteristics and disposition. The ITT population comprised 982 patients in RAPID 1 (certolizumab pegol 200 : n 393, certolizumab pegol 400 : n 390, placebo: n 199). Baseline patient demographics and disease activity were comparable across treatment groups, with all core set values indicating that patients had high baseline disease activity (5) (see Supplementary Table 1, available in the online version of this article at ). Improvements in the signs and symptoms of RA. Certolizumab pegol 200 plus MTX conferred significantly greater benefit than placebo plus MTX according to ACR20 responder rates (dichotomous measure) (Figure 1A), ACR s (hybrid measure) (Figure 1B), and mean change from baseline in the DAS28 (continuous measure) (Figure 1C). By all 3 measures, responses to certolizumab pegol 200 plus MTX were significantly greater than placebo plus MTX by week 1, continued to improve through the first 12 weeks of treatment, and were sustained to study end (Figure 1). ACR20 response rates were similar in the certolizumab pegol 400 plus MTX group as previously reported (5), as were mean changes from baseline in the DAS28 and ACR s (data not shown). Comparison between ACR s and ACR20 response rates. ACR s were then compared with ACR20 response rates, and ACR s at weeks 1 and 52 were further analyzed. For simplicity, the remainder of this study focuses on comparisons between the placebo plus MTX and the certolizumab pegol 200 plus MTX groups. Response at week 1. At week 1, the ACR20 response rate was significantly higher in the certolizumab pegol treated patients compared with the placebo plus MTX treated patients (22.9% versus 5.6%; P by logistic regression). Similarly, the median ACR s were also significantly higher in the certolizumab pegol group than in the placebo group (19.99 versus 2.76; P by rank analysis). The significant improvement at week 1 with certolizumab pegol is further evidenced by the rightward shift in the distribution of ACR s in patients treated with certolizumab pegol 200 plus MTX versus those treated with placebo plus MTX (Figure 2A). Figure 1. Efficacy of certolizumab pegol 200 plus methotrexate (MTX) versus placebo plus MTX over time in the treatment of active rheumatoid arthritis in the intent-to-treat population of the Rheumatoid Arthritis Prevention of Structural Damage 1 trial. Responses were significantly greater in patients treated with certolizumab pegol 200 plus MTX versus placebo plus MTX (P at weeks 1 52). A, American College of Rheumatology (ACR) 20% response criteria (ACR20) response rates (logistic regression, nonresponder imputation). B, Median ACR hybrid scores (analysis of covariance [ANCOVA] on the ranks, last observation carried forward [LOCF] imputation). C, Mean changes from baseline in the Disease Activity Score in 28 joints (DAS28; erythrocyte sedimentation rate [ESR]) (ANCOVA, LOCF imputation). Part A adapted, with permission, from ref. 1. The median ACR of indicates that at least half of the patients treated with certolizumab pegol
4 Assessing Effective Treatment for RA With ACR Hybrid Analysis 131 Figure 2. Distribution of American College of Rheumatology (ACR) s (last observation carried forward imputation) over time in patients treated with certolizumab pegol 200 plus methotrexate (MTX) versus placebo plus MTX in the Rheumatoid Arthritis Prevention of Structural Damage 1 trial. The number of subjects in the analysis varies slightly from the intent-to-treat population numbers due to nonimputable missing data for each visit. A, Week 1 (certolizumab pegol 200 plus MTX group: n 385, placebo plus MTX group: n 194). B, Week 12 (certolizumab pegol 200 plus MTX group: n 391, placebo plus MTX group: n 196). C, Week 52 (certolizumab pegol 200 plus MTX group: n 392, placebo plus MTX group: n 196). plus MTX had at least a 20% mean improvement in core set measures at week 1 of treatment. Table 2, which indicates the number of patients in each ACR hybrid category (as defined in Table 1), shows that 197 (51.2%) of 385 certolizumab pegol treated patients had at least a 20% mean improvement at week 1. Of these, only 88 patients (less than half of those with a mean improvement of 20%) had a concurrent ACR20 response (Table 2). These results indicate that the ACR hybrid may be more sensitive than the ACR20 in detecting small improvements, such as those that occurred early on during treatment. In contrast, the median ACR of 2.76 in the placebo plus MTX group, together with the distribution of ACR s shown in Figure 2A, indicate that the majority of patients treated with MTX alone had a minimal mean improvement in, or a worsening of, ACR core set measures at week 1. At week 1, only 28 (14.4%) of 194 patients in the placebo plus MTX group had at least a 20% mean improvement in ACR core set measures, and of these, 11 had a concurrent ACR20 response (Table 2). Response over time (weeks 1 52). The median ACR hybrid score remained at through week 4 for patients treated with certolizumab pegol plus MTX (Figure 1B), during which time the proportion of patients meeting the criteria for ACR20 response increased to 43.6% (Figure 1A). Most of the shift in the ACR was achieved after 12 weeks of treatment and was indicative of outcomes at 52 weeks. After 50% of the patients had achieved an ACR20 response, the median ACR hybrid score improved to at week 12 (Figures 1B and 2) and remained stable at thereafter from week 16 to week 52 (i.e., at least 50% of patients had a mean improvement in core measures of 50% at week 52). Similarly, the ACR20 response rate reached 63.8% at week 12 and also remained stable to week 52. The distribution of ACR s at weeks 12 and 52 demonstrates peaks at scores of 20, 50, and 70 for patients treated with certolizumab pegol plus MTX (Figures 2B and C). These peaks reflect the banding of ACR s according to the ACR20, ACR50, or ACR70 response achieved and the level of improvement in the ACR components (Table 1). Although each peak mostly included patients who had a mean improvement in the ACR core set measures greater than the 20%/50%/70% threshold, but who did not meet the formal threshold definition for an ACR20/50/70 response, respectively (e.g., did not have an ACR20 response, but had a mean improvement of 20%), the peaks also included patients who met the criteria for an ACR20/50/70 response, but had a mean core set improvement of less than or equal to the respective threshold. For example, analysis of the distribution peak at the ACR of 20 at week 52 showed that 4 (6.8%) of 59 or 1 (3.7%) of 27 of the certolizumab pegol 200 or placebo-treated patients at the peak, respectively, were ACR20 responders with a mean improvement in ACR core set measures of 20% (i.e., an ACR of 20.00). In contrast, 55 (93.2%) of 59 or 26 (96.3%) of 27 of the certolizumab pegol 200 or placebo-treated patients, respectively, were ACR20 nonresponders, with a mean improvement in the ACR core set measures of 20% (i.e., an ACR of 19.99) at week 52, demonstrating that the ACR20 response rate may underestimate treatment benefit (Table 3). Of the 55 certolizumab pegol 200 treated patients with an ACR of 19.99, approximately half (49.1%) failed to achieve an ACR20 response because they failed to achieve an improvement of 20% in tender and/or swollen joint counts. Likewise, analysis of the distribution peaks at the ACR hybrid of approximately 50 showed that these peaks primarily consisted of patients with an ACR of 49.99, with 51 (85.0%) of 60 or 3 (75.0%) of 4 of the certolizumab pegol 200 or placebo-treated patients, respectively, having an average improvement in ACR core set measures of at least 50% without a concurrent ACR50 response at week 52 (Table 3). Of the 51 certolizumab pegol 200 treated patients with an ACR of 49.99, 43.1% had an improvement in tender joint count
5 132 van Vollenhoven et al Table 2. Number and percentage of patients within each ACR hybrid (LOCF) category at week 1 in the Rheumatoid Arthritis Prevention of Structural Damage 1 trial* <20 >20, <50 >50, <70 >70 ACR status Not ACR20, ACR Mean % Mean % Patients, no. (%) 188 (48.8) 166 (85.6) 106 (27.5) 17 (8.8) 3 (0.8) ACR20 but not ACR50, ACR Mean % Mean % Patients, no. (%) (12.5) 5 (2.6) 21 (5.5) 2 (1.0) 2 (0.5) 0 ACR50 but not ACR70, ACR Mean % Mean % Patients, no. (%) (0.3) 0 8 (2.1) 4 (2.1) 6 (1.6) 0 ACR70, ACR n/a n/a Mean % Mean % Patients, no. (%) n/a n/a (0.3) 0 1 (0.3) 0 * methotrexate (MTX) group: n 385, placebo MTX group: n 194 (the number of subjects in the analysis varies slightly from the intent-to-treat population numbers due to nonimputable missing data). ACR American College of Rheumatology; LOCF last observation carried forward; CZP certolizumab pegol; ACR20 ACR 20% response criteria; n/a not applicable. ACR status by LOCF analysis. and/or swollen joint count of 50% and so did not achieve an ACR50 response. Interestingly, median ACR s in patients treated with placebo plus MTX remained low ( 10) throughout the study (Figure 1B), with scores of 9.96 and 6.67 at weeks 12 and 52, respectively (Figures 2B and C), indicating that the mean response of placebo-treated patients on the ACR core set measures was minimal during the study. Furthermore, at week 52, 39.8% of placebotreated patients had an ACR of 0 and 15.3% had a 20% worsening in the mean ACR components (compared with 6.6% and 2.3%, respectively, of patients treated in the certolizumab pegol 200 plus MTX group). DISCUSSION ACR20/50/70 scores have provided a standardized response measure in RA clinical trials for more than 10 years, allowing for important comparisons of efficacy to be made between treatments and consistency in reporting of clinical trial results, and facilitating approval of 7 diseasemodifying antirheumatic drugs since 1998 (1). Until that time, the measures that were used to assess treatment efficacy typically assessed mean or median improvements. Although these continuous measures conferred sensitivity to distinguish between treatments, they only provided information on the average level of improvement for the population and did not indicate the percentage of patients Table 3. Number and percentage of patients within each ACR hybrid (LOCF) category at week 52 in the Rheumatoid Arthritis Prevention of Structural Damage 1 trial* <20 >20, <50 >50, <70 >70 ACR status Not ACR20, ACR Mean % Mean % Patients, no. (%) 79 (20.2) 128 (65.3) 47 (12.0) 26 (13.3) 6 (1.5) 0 2 (0.5) 0 ACR20 but not ACR50, ACR Mean % Mean % Patients, no. (%) 4 (1.0) 1 (0.5) 31 (7.9) 19 (9.7) 46 (11.7) 3 (1.5) 5 (1.3) 0 ACR50 but not ACR70, ACR Mean % Mean % Patients, no. (%) (2.3) 1 (0.5) 48 (12.2) 9 (4.6) 17 (4.3) 2 (1.0) ACR70, ACR n/a n/a Mean % Mean % Patients, no. (%) n/a n/a (2.3) 3 (1.5) 89 (22.7) 4 (2.0) * methotrexate (MTX) group: n 392, placebo MTX group: n 196 (the number of subjects in the analysis varies slightly from the intent-to-treat population numbers due to nonimputable missing data). ACR American College of Rheumatology; LOCF last observation carried forward; CZP certolizumab pegol; ACR20 ACR 20% response criteria; n/a not applicable. ACR status by LOCF analysis.
6 Assessing Effective Treatment for RA With ACR Hybrid Analysis 133 who improved (1). Although the ACR20/50/70 scores address the question as to the proportion of patients that respond, they are dichotomous (indicating whether a treatment response is present or absent), so they may likely underestimate response and may have limited sensitivity to change and ability to gauge differences between treatments. In response to these limitations, the ACR hybrid was developed. The ACR combines conventional ACR20/50/70 scores with the mean percent improvement in all 7 ACR core set components. Importantly, this new measure is linked to ACR20/50/70 scores to allow for continuity of standardized reporting (i.e., the median ACR indicates whether at least 50% of patients achieved an ACR20, ACR50, or ACR70 response or no response), but also indicates the average response of the population (like the DAS28). Taken together, the ACR hybrid gives the percent improvement from baseline on a continuous scale of change and facilitates the detection of modest differences between therapies in RA clinical trials (3). Our analysis demonstrated that the ACR hybrid provided complementary results to DAS28 change from baseline and to the conventional ACR20, with all measures showing that certolizumab pegol treated patients had significantly greater improvements than placebo-treated patients from week 1 through study end. The majority of improvement in ACR s was achieved before 12 weeks and was maintained up to week 52, indicating that assessment at week 12 can be used as an indicator of outcome after 1 year. Comparison between the ACR hybrid scores and the ACR response rates suggests that the latter measure may underestimate differences between active treatment and placebo. One limitation of the ACR hybrid is that, because of its use of ACR20, ACR50, and ACR70 thresholds, there are clusters of scores at each of these thresholds rather than a continuum of scores. For example, the median value will be until at least 50% of patients achieve an ACR50 response. This limitation can be overcome by presentation of the data in histograms, which provide considerably more information than the ACR response rates, showing the distribution of response across the population as well as indicating the proportion of patients that improve. Analysis of the distribution of the peaks at ACR s of 20, 50, and 70 showed that a proportion of patients receiving active treatment who did not have an ACR response still had improvements in ACR core set measures. The majority of certolizumab pegol treated patients in these peaks had scores of 19.99, 49.99, or versus 20, 50, or 70, meaning that they achieved an average improvement in ACR core set measures of at least 20%, 50%, or 70%, respectively, while not achieving actual ACR20, ACR50, or ACR70 responses, respectively. In these patients, this failure to achieve ACR20/50/70 responses was frequently due to a lack of improvement in the swollen and/or tender joint count. The ACR hybrid measure also incorporates worsening of disease activity, so it may provide a better assessment of the overall average change in disease activity during the course of a clinical trial. This is particularly important for patients who receive placebo in clinical trials because they are more likely to show worsening, or at least inconsistent changes, from one core set measure to another, whereas patients receiving active treatment often experience improvement (9). -treated patients are therefore likely to have worse (or even negative) ACR s compared with patients receiving active treatment, thereby permitting easy discrimination of effective treatment from placebo. Consistent with this, our ACR hybrid analysis found that 15% of patients in the placebo group had a worsening in ACR core components of 20% at the end of the study and the average clinical response to placebo plus MTX was negligible throughout (40% of placebo-treated patients had an ACR of 0). The mean change from baseline in the DAS28 measure also demonstrated that the response to placebo and MTX was low; however, unlike the ACR hybrid, mean change data give no indication of the proportion of patients who achieved an average response. In contrast, the ACR20 responder rates to placebo ranged from 10% to 20%, consistent with placebo response rates in other RA clinical trials (5,10 16). Our results should be considered an impetus for future prospective studies that employ the ACR as a primary end point. These clinical trials may require fewer patients for measurement of efficacy due to the increased sensitivity of the ACR hybrid. The observation that patients randomized to placebo plus MTX experienced, on average, a negligible benefit (and that some placebo-treated patients had disease worsening) throughout the trial reinforces concerns about extended placebo treatment in RA clinical trials and supports the use of an early rescue arm as used in RAPID 1. In conclusion, post hoc analysis of RAPID 1 using the ACR confirms the value of this response criterion in clinical studies and reinforces the validity of traditional ACR20/50/70 scores. ACKNOWLEDGMENTS We would like to thank Lucian Ionescu, Owen Davies, and Lee Gervitz, employees of UCB, for critically reviewing the manuscript. We would also like to acknowledge the medical writing assistance and editorial services of Karen Munro and Linda Wychowski from PAREXEL, which was funded by UCB. AUTHOR CONTRIBUTIONS All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication. Dr. van Vollenhoven had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design. Van Vollenhoven, Felson, Strand, Weinblatt, Keystone. Acquisition of data. Van Vollenhoven, Strand. Analysis and interpretation of data. Van Vollenhoven, Felson, Strand, Weinblatt, Luijtens, Keystone. ROLE OF THE STUDY SPONSOR UCB contributed to the study design and to the collection, analysis, and interpretation of the data. The trial on which the
7 134 van Vollenhoven et al current analysis was based (the Rheumatoid Arthritis Prevention of Structural Damage 1 trial) was a phase III clinical trial fully supported by the sponsor, and the data from this trial are owned by the sponsor. The first author of this paper (RFvV) approached the sponsor with the suggestion to perform the current analysis (which was not part of the original study plan, as the American College of Rheumatology hybrid was not yet known at that time) and was given the opportunity to undertake this with the other coauthors, some of whom are employees of the sponsor and others who are academicians. At that time it was also agreed to publish the results of the analysis, and no further approval was needed thereafter. REFERENCES 1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38: Van Gestel AM, Prevoo ML, van t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39: American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 2007;57: Smolen JS, Aletaha D. Activity assessments in rheumatoid arthritis. Curr Opin Rheumatol 2008;20: Keystone E, van der Heijde D, Mason D, Landewe R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fiftytwo week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58: Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31: Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35: Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36: Anderson JJ, Bolognese JA, Felson DT. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Arthritis Rheum 2003;48: Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al, for the Anti Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50: Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354: Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340: Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50: Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, and the Anti Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343: Smolen JS, Landewe R, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68:
Received: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More informationThe Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 63, No. 5, May 2011, pp 1200 1210 DOI 10.1002/art.30263 2011, American College of Rheumatology The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results
More informationAppendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview. Trial duration in months
Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview Study Name Year Reference ABATACEPT (n=7) Moreland 2002 Moreland LW, Alten R, Van den Bosch
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationCLINICAL BRIEFS. Tumor Necrosis Factor Inhibitors In the Treatment of Chronic Inflammatory Diseases
CLINICAL BRIEFS Tumor Necrosis Factor Inhibitors In the Treatment of Chronic Inflammatory Diseases A review of immunogenicity and potential implications By Joseph Flood, MD, FACR President, Musculoskeletal
More informationG Wells, 1 J-C Becker, 2 J Teng, 2 M Dougados, 3 M Schiff, 4 J Smolen, 5 D Aletaha, 6 P L C M van Riel 7. Extended report
1 Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada; 2 Bristol-Myers Squibb, Princeton, New Jersey, USA; 3 Paris-Descartes University, Medicine Faculty and UPRES-EA
More informationT. Pincus 1, B. Richardson 2, V. Strand 3, M.J. Bergman 4
Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents T. Pincus 1, B. Richardson 2,
More informationOptimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
RHEUMATOLOGY Rheumatology 2012;51:v12 v21 doi:10.1093/rheumatology/kes111 Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs Karel
More informationOPEN ACCESS EXTENDED REPORT. Clinical and epidemiological research
OPEN ACCESS 1 Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 2 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands 3 Department
More informationI nfliximab has emerged as an effective treatment for
1233 EXTENDED REPORT Double-blinded infliximab dose escalation in patients with rheumatoid arthritis Mahboob U Rahman, Ingrid Strusberg, Piet Geusens, Alberto Berman, David Yocum, Daniel Baker, Carrie
More informationEfficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
To cite: Fleischmann RM, Huizinga TWJ, Kavanaugh AF, et al. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2016;2:e000262. doi:10.1136/rmdopen-2016-000262
More informationExtended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;
1 Denver Arthritis Clinic, Denver, Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; 3 Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; 4 Arthritis &
More informationExtended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate
More informationThe Journal of Rheumatology Volume 41, no. 2
The Volume 41, no. 2 Clinical, Functional, and Radiographic Implications of Time to Treatment Response in Patients With Early Rheumatoid Arthritis: a Posthoc Analysis of the PREMIER Study Edward C. Keystone,
More informationTumor Necrosis Factor Therapy and the Risk of Serious Infection and Malignancy in Patients With Early Rheumatoid Arthritis
ARTHRITIS & RHEUMATISM Vol. 63, No. 6, June 2011, pp 1479 1485 DOI 10.1002/art.30310 2011, American College of Rheumatology Tumor Necrosis Factor Therapy and the Risk of Serious Infection and Malignancy
More informationWhat I Have Learned Over the Years - Keystone s Top 10 -
What I Have Learned Over the Years - Keystone s Top 10 - Edward Keystone, MD FRCP(C) Professor of Medicine University of Toronto, CANADA Ontario Rheumatology Association Meeting Muskoka, Canada Sunday,
More informationMETHODS In the context of an indirect comparison metaanalysis between tocilizumab and other biological
c Additional data are published online only at http://ard.bmj. com/content/vol69/issue1 Correspondence to: Professor M Boers, Department of Epidemiology and Biostatistics, VU University Medical Centre,
More informationEvaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data
c Additional supplemental tables are published online only at http://ard.bmj.com/content/ vol68/issue4 1 Rene Descartes University, Medicine Faculty, UPRES EA 4058, APHP, Cochin Hospital, Rheumatology
More informationKey Words: Rheumatoid Arthritis, etanercept, post-marketing study, comparative study
CLINICAL DATA GAP BETWEEN PHASE III CLINICAL TRIALS (PRE-MARKETING) AND PHASE IV (POST-MARKETING) STUDIES: EVALUATION OF ETANERCEPT IN RHEUMATOID ARTHRITIS Pendar Farahani 1,3, Mitchell Levine 1,2, Kathryn
More informationAbatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor a Inhibition
The new england journal of medicine original article Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor a Inhibition Mark C. Genovese, M.D., Jean-Claude Becker, M.D., Michael Schiff,
More informationCorrespondence should be addressed to Martin J. Bergman;
Autoimmune Diseases Volume 2013, Article ID 367190, 7 pages http://dx.doi.org/10.1155/2013/367190 Research Article Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive
More informationM Schiff, 1 C Pritchard, 2 J E Huffstutter, 3 V Rodriguez-Valverde, 4 P Durez, 5 X Zhou, 6 T Li, 6 K Bahrt, 6 S Kelly, 6 M Le Bars, 7 M C Genovese 8
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
More informationM Schiff, 1 C Pritchard, 2 J E Huffstutter, 3 V Rodriguez-Valverde, 4 P Durez, 5 X Zhou, 6 T Li, 6 K Bahrt, 6 S Kelly, 6 M Le Bars, 7 M C Genovese 8
1 University of Colorado, Denver, Colorado, USA; 2 Rheumatology Specialty Center, Willow Grove, Pennsylvania, USA; 3 Arthritis Associates, Hixson, Tennessee, USA; 4 Hospital Universitario Marques De Valdecilla,
More informationDevelopment of Classification and Response Criteria for Rheumatic Diseases
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 55, No. 3, June 15, 2006, pp 348 352 DOI 10.1002/art.22003 2006, American College of Rheumatology EDITORIAL Development of Classification and Response
More informationWhat does it mean for Pharmacists?
18th Congress of the European Association of Hospital Pharmacists (EAHP) Paris, 14 March 2013 What does it mean for Pharmacists? Value-based Decision Making in Rheumatic Disease Pr. REES France 28, Rue
More informationjournal of medicine The new england Therapies for Active Rheumatoid Arthritis after Methotrexate Failure A BS TR AC T
The new england journal of medicine established in 1812 july 25, 2013 vol. 369 no. 4 Therapies for Active Rheumatoid Arthritis after Methotrexate Failure James R. O Dell, M.D., Ted R. Mikuls, M.D., M.S.P.H.,
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationConcept of Measurement: RA Defining Decrements in Physical Function
Concept of Measurement: RA Defining Decrements in Physical Function Vibeke Strand, MD Biopharmaceutical Consultant Adjunct Clinical Professor, Division of Immunology, Stanford University Disclosures: Consultant
More information10/28/2013. Disclosures. Objectives. Background. Study Design. Key Inclusion Criteria
Randomization (1:1:1:1) /28/13 Tocilizumab in Combination Therapy and Monotherapy Versus Methotrexate in Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationAn Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis Michael E. Weinblatt, M.D., Arthur Kavanaugh, M.D., Mark C.
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationFalk Hiepe,5 Dinesh Khanna,6 Enkeleida Nikaï,7 Geoffroy Coteur,8 Michael Schiff9
Additional data (supplementary tables and fi gures) are published online only. To view these fi les please visit the journal online (http://ard.bmj.com) 1 Division of Immunology/ Rheumatology, Stanford
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationORIGINAL ARTICLE DANIEL E. FURST, 1 AILEEN L. PANGAN, 2 LESLIE R. HARROLD, 3 HONG CHANG, 4 GEORGE REED, 3 JOEL M. KREMER, 5 AND JEFFREY D.
Arthritis Care & Research Vol. 63, No. 6, June 2011, pp 856 864 DOI 10.1002/acr.20452 2011, American College of Rheumatology ORIGINAL ARTICLE Greater Likelihood of Remission in Rheumatoid Arthritis Patients
More informationOpen Access NY, USA. Keywords: HAQ, early RA, disease activity, DAS, cohort, correlation, longitudinal.
Send Orders for Reprints to reprints@benthamscience.net 58 The Open Rheumatology Journal, 2013, 7, 58-63 Open Access The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28
More informationResearch Article. Robin Christensen* 1,2, Simon Tarp 1, Daniel E Furst 3, Lars E Kristensen 1,4 & Henning Bliddal 1
Research Article Efficacy and safety of infliximab or adalimumab, versus abatacept, in patients with rheumatoid arthritis: ATTEST AMPLE network randomized trial Our objective was to assess the efficacy
More informationThe new ACR/EULAR remission criteria: rationale for developing new criteria for remission
RHEUMATOLOGY Rheumatology 2012;51:vi16 vi20 doi:10.1093/rheumatology/kes281 The new ACR/EULAR remission criteria: rationale for developing new criteria for remission Vivian P. Bykerk 1,2 and Elena M. Massarotti
More informationComparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
7 Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Charlotte Krieckaert* Anna Jamnitski* Mike Nurmohamed Piet Kostense
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationCADTH Therapeutic Review Panel
Therapeutic Review Panel Final Recommendations Biological Response Modifier Agents for Adults with Rheumatoid Arthritis July 2010 RECOMMENDATIONS The Therapeutic Review Panel (TRP) recommends that in adult
More informationK., "Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior antitumour
University of Massachusetts Medical School escholarship@umms Rheumatology Publications and Presentations Rheumatology 10-2014 Insights into the efficacy of golimumab plus methotrexate in patients with
More informationComprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?
Handling editor Tore K Kvien 1 Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching
More informationBiologic therapy with antagonists to tumor necrosis factor
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:696 702 Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn s Disease: Results From the PRECiSE 4 Study WILLIAM J. SANDBORN,* STEFAN SCHREIBER,
More informationTwo Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
Arthritis Care & Research Vol. 67, No. 2, February 2015, pp 151 160 DOI 10.1002/acr.22496 2015 The Authors. Arthritis Care & Research is published by Wiley Periodicals, Inc. on behalf of the American College
More informationM. Schoels 1, F. Alasti 2, J. S. Smolen 1,2 and D. Aletaha 2*
Schoels et al. Arthritis Research & Therapy (2017) 19:155 DOI 10.1186/s13075-017-1346-5 RESEARCH ARTICLE Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28)
More informationTofacitinib versus Methotrexate in Rheumatoid Arthritis
The new england journal of medicine original article Tofacitinib versus in Rheumatoid Arthritis Eun Bong Lee, M.D., Roy Fleischmann, M.D., Stephen Hall, M.D., Bethanie Wilkinson, Ph.D., John D. Bradley,
More informationStructural damage in rheumatoid arthritis as visualized through radiographs Désirée van der Heijde
Structural damage in rheumatoid arthritis as visualized through radiographs Désirée van der Heijde University Hospital Maastricht, Maastricht, The Netherlands; and Limburg University Center, Diepenbeek,
More informationProgress Toward the Cure of Rheumatoid Arthritis? The BeSt Study
ARTHRITIS & RHEUMATISM Vol. 52, No. 11, November 2005, pp 3326 3332 DOI 10.1002/art.21503 2005, American College of Rheumatology EDITORIAL Progress Toward the Cure of Rheumatoid Arthritis? The BeSt Study
More informationHead-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
Handling editor Tore K Kvien For numbered affiliations see end of article. Correspondence to Dr Michael Schiff, University of Colorado, School of Medicine, 5400 South Monaco Street, Greenwood Village,
More informationEffect of Etanercept on Fatigue in Patients With Recent or Established Rheumatoid Arthritis
Arthritis & Rheumatism (Arthritis Care & Research) Vol. 55, No. 2, April 15, 2006, pp 287 293 DOI 10.1002/art.21838 2006, American College of Rheumatology ORIGINAL ARTICLE Effect of Etanercept on Fatigue
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationKey words: rheumatoid arthritis, anti-tnf, methotrexate, outcomes research, randomized controlled trials
RHEUMATOLOGY Rheumatology 2017;56:725 735 doi:10.1093/rheumatology/kew467 Advance Access publication 7 January 2017 Original article Efficacy and effectiveness of tumour necrosis factor inhibitors in the
More informationDivision of Rheumatology, Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland 4
Original papers Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population Sławomir Jeka 1,A,B,D F, Bogdan
More informationOriginal article RHEUMATOLOGY
RHEUMATOLOGY Rheumatology 2015;54:2188 2197 doi:10.1093/rheumatology/kev249 Advance Access publication 21 July 2015 Original article Final 10-year effectiveness and safety results from study DE020: adalimumab
More informationN Nishimoto, 1 N Miyasaka, 2 K Yamamoto, 3 S Kawai, 4 T Takeuchi, 5 J Azuma 1. Extended report
1 Osaka University, Osaka, Japan; 2 Tokyo Medical and Dental University, Tokyo, Japan; 3 University of Tokyo, Tokyo, Japan; 4 Toho University Omori Medical Center, Tokyo, Japan; 5 Saitama Medical Center/
More informationQuality of life in patients with rheumatoid arthritis: Does abatacept make a difference?
Quality of life in patients with rheumatoid arthritis: Does abatacept make a difference? K. Michaud 1, C. Bombardier 2, P. Emery 3 1 University of Nebraska Medical Center, Omaha, NE; 2 Institute for Work
More informationDose optimization of infliximab in patients with rheumatoid arthritis
International Journal of Rheumatic Diseases 2014; 17: 5 18 REVIEW ARTICLE Dose optimization of infliximab in patients with rheumatoid arthritis Rieke ALTEN 1 and Filip VAN DEN BOSCH 2 1 Department of Internal
More informationintolerance to tumour necrosis
To cite: Nash P, Behrens F, Orbai A-M, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic diseasemodifying antirheumatic drugs (cdmards) in patients with active psoriatic
More informationMeasuring Patient Outcomes:
Measuring Patient Outcomes: Interplay of science, policy and marketing Chapel Hill, November 22, 22 Dr. Claire Bombardier Professor of Medicine, University of Toronto Senior Scientist, Institute for Work
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationTNF inhibitor therapy for rheumatoid arthritis (Review)
BIOMEDICAL REPORTS 1: 177-184, 2013 TNF inhibitor therapy for rheumatoid arthritis (Review) XIXI MA and SHENGQIAN XU Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical
More informationRESEARCH ARTICLE. Yang Liu 1, 3, Wei Fan 2, Hao Chen 2, Ming-Xia Yu 2 * Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.8.3403 Risk of Cancer in Rheumatoid Arthritis Patients Undergoing TNF-α Antagonists Therapy: a Meta-Analysis RESEARCH ARTICLE Risk of Breast Cancer and Total
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationKeywords Rheumatoid arthritis Infliximab Total van der Heijde Sharp score Joint destruction. Introduction
Mod Rheumatol (2008) 18:447 454 DOI 10.1007/s10165-008-0077-5 ORIGINAL ARTICLE Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management
More informationF. Wolfe 1,2 and K. Michaud 1,3
Rheumatology 2005;44(Suppl. 4):iv18 iv22 Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness
More informationPhysical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
Radner et al. Arthritis Research & Therapy (2015) 17:203 DOI 10.1186/s13075-015-0719-x RESEARCH ARTICLE Open Access Physical function continues to improve when clinical remission is sustained in rheumatoid
More informationABSTRACT Background. Methods. Results. Conclusions
Chapter 3 Clinical response to adalimumab: the relationship with antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis G.M. Bartelds C.A. Wijbrandts M.T. Nurmohamed S. Stapel
More informationR heumatoid arthritis is a chronic inflammatory disease with
1443 EXTENDED REPORT Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy
More informationGolimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis
Clinical Medicine Reviews in Therapeutics Review Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Lauren Keyser McCluggage 1 and Kelly Michelle
More informationR heumatoid arthritis (RA) is an idiopathic autoimmune
508 EXTENDED REPORT Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed L B A van de Putte,
More informationISSN: (Print) (Online) Journal homepage:
Modern Rheumatology ISSN: 1439-7595 (Print) 1439-7609 (Online) Journal homepage: http://www.tandfonline.com/loi/imor20 Efficacy and safety of certolizumab pegol without methotrexate co-administration in
More informationABSTRACT ORIGINAL RESEARCH
Rheumatol Ther (2018) 5:203 214 https://doi.org/10.1007/s40744-018-0093-7 ORIGINAL RESEARCH Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients
More informationSustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis
The new england journal of medicine Original Article Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis Paul Emery, F.R.C.P., Mohammed Hammoudeh, M.D., Oliver FitzGerald, M.D.,
More informationPsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL.
RA Rheumatoid arthritis PsA Psoriatic arthritis AS Ankylosing spondylitis EFFICACY EFFICACY EFFICACY QoL QoL QoL SAFETY SAFETY SAFETY EXPERIENCE EXPERIENCE EXPERIENCE SUMMARY SUMMARY SUMMARY Copyright
More informationReceived: 28 November 2007 / Revised: 11 February 2008 / Accepted: 12 February 2008 / Published online: 19 March 2008 # The Author(s) 2008
Clin Rheumatol (08) 27:1021 1028 DOI 10.1007/s10067-008-0866-4 ORIGINAL ARTICLE An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationComparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
Harrold et al. Arthritis Research & Therapy (2016) 18:280 DOI 10.1186/s13075-016-1179-7 RESEARCH ARTICLE Open Access Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationPostmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
DOI 10.1007/s10165-010-0406-3 ORIGINAL ARTICLE Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis Takao Koike Masayoshi Harigai Shigeko
More informationReview Does route of administration affect the outcome of TNF antagonist therapy? Sergio Schwartzman 1 and G James Morgan Jr 2
Review Does route of administration affect the outcome of TNF antagonist therapy? Sergio Schwartzman 1 and G James Morgan Jr 2 1 Hospital for Special Surgery, New York, NY, USA 2 Dartmouth-Hitchcock Medical
More informationA network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
CMAJ Research A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview Jasvinder A. Singh MD, Robin Christensen PhD, George A. Wells PhD, Maria
More informationTofacitinib (CP-690,550) in Patients With Rheumatoid Arthritis Receiving Methotrexate
ARTHRITIS & RHEUMATISM Vol. 65, No. 3, March 2013, pp 559 570 DOI 10.1002/art.37816 2013, American College of Rheumatology Tofacitinib (CP-690,550) in Patients With Rheumatoid Arthritis Receiving Methotrexate
More informationClinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
1 UZ Gasthuisberg, Leuven, Belgium; 2 Centro Médico Toluca, Metepec, México; 3 Hospital Geral de Goiânia, Goiânia, Brazil; 4 St Augustine s Hospital, Durban, South Africa; 5 Klinikum Eilbek, Hamburg, Germany;
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationTofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients
doi: 10.2169/internalmedicine.9341-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationABSTRACT ORIGINAL RESEARCH
https://doi.org/10.1007/s40744-018-0113-7 ORIGINAL RESEARCH Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan
More informationRelative effect (95% CI) RR LOW 2,3 due to indirectness, imprecision. RR 1.45 (0.43 to 4.84) due to indirectness, imprecision. (0.18 to 20.
Appendix: Evidence Reports Question In patients with early RA with moderate or high disease activity, who are DMARD-naive, what is the impact of combination double DMARD therapy vs. mono-dmard therapy
More informationReviews and Opinions 1 RA. Key words rheumatoid arthritis biologics remission bone joint destruction. rheumatoid arthritis RA 10
Reviews and Opinions Key words rheumatoid arthritis biologics remission bone joint destruction Spinal Surgery27113212013 rheumatoid arthritisra 10 TNFtumor necrosis factoril6 interleukin6 RA DMARDsdisease
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23689
More information